Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Pamidronic acid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jan 31, 2028 · 522 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pamidronsäure (ATC-Code nach WHO: M05BA03)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...

Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Pamidronic acid (ATC M05BA03).
  • Open-house participation model allowing eligible pharmaceutical companies to join during the participation period.
Pokaż pełne podsumowanie

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Pamidronic acid (ATC M05BA03) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but no procurement document text was provided for analysis, so several submission details remain document-dependent and incomplete.

Ryzyka

The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...

Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.
  • The company must accept the participation conditions and the rebate agreement terms.

Eligibility

  • Submission of the completed declaration on the absence of exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Pamidronic acid

Single lot for concluding non-exclusive pharmaceutical rebate agreements for medicines containing Pamidronic acid (ATC M05BA03). The lot is a supply arrangement under an open-house model; no exclusivity, no guaranteed minimum purchase volume, and the contract may be concluded with all interested eligible pharmaceutical companies during the participation period. Place of performance is Dresden, Germany, with broader reference to Saxony and Thuringia in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jan 2026 - Jan 2028

Kategoria

Pharmaceutical products

Termin

Deadline Jan 31, 2028

Szczegóły zamówienia

Data publikacji
19 Oct 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
687423-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3